Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 4, 2017, Pages e21-e23

  Emmi, Giacomo ^a,b   Urban, Maria Letizia ^c   Scalera, Antonella ^a   Becatti, Matteo ^a   Fiorillo, Claudia ^a   Silvestri, Elena ^a,b   Prisco, Domenico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; RITUXIMAB; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; B LYMPHOCYTE; BLOOD TOXICITY; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PNEUMONIA; RECURRENCE FREE SURVIVAL; RELAPSE; REMISSION; RETREATMENT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY CARE CENTER; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RITUXIMAB;

EID: 84994691777     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.08.002     Document Type: Letter

References (4)

1. [1] Wang, C.R., Liu, M.F., Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience. Semin Arthritis Rheum 46 (2016), 102–108.
2. [2] Calich, A.L., Puéchal, X., Pugnet, G., London, J., Terrier, B., Charles, P., et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. J Autoimmun 50 (2014), 135–141.
3. [3] Al Marzooqi, A., Leone, A., Al Saleh, J., Khamashta, M., Current status and future prospects for the treatment of antiphospholipid syndrome. Expert Rev Clin Immunol 12 (2016), 1–9.
4. [4] Mok, C.C., Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis 18 (2015), 154–163.